flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 FLOW- the Visual Abstract — NephJC New Science Suggests Semaglutide Improves
Description
It is good to talk openly with your healthcare team
Eat slowly and stop at comfortable, not full. Because the stomach empties more slowly, eating fast can lead to discomfort or nausea
Significant weight loss typically occurs over three to six months
Fits the context
All descriptions are based on publicly available information from Direct Meds' website, support documentation, and general GLP-1 medication research
Ongoing Medical Supervision and Dose Optimization MEDVi's model emphasizes that GLP-1 therapy requires sustained medical oversight, not simply initial prescription followed by patient self-management
